A0A140T913 (A0A140T913_HUMAN) Homo sapiens (Human)
HLA class I histocompatibility antigen, A alpha chain UniProtKBInterProInteractive Modelling
371 aa; Sequence (Fasta)
It is possible new templates exist for this target since these models were created.
Available Structures
50 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Ligands | ||
|---|---|---|---|---|---|---|
| MHC Class I A02 Allele presenting EAAGIGILTV, in complex with Mel8 TCR |
Heteromer P61769; Q16655; | 2×EDO; | ||||
| Assess | ||||||
| SARS-CoV-2 spike-derived peptide S1060-1068 (VVFLHVTYV) presented by HLA-A*02:01 |
Heteromer P0DTC2; P61769; | 2×CD; 1×NA; | ||||
| Assess | ||||||
| TCR mimic antibody (Fab fragment) in complex with AFP/HLA-A*02 |
Heteromer P02771; P61769; | 1×1PE; 1×FMT; 4×GOL; 2×PG4; 1×PGE; 1×EPE; | ||||
| Assess | ||||||
| Crystal structure of engineered TCR (756) complexed to HLA-A*02:01 presenting MAGE-A10 9-mer peptide |
Heteromer P43363; P61769; | 4×GOL; | ||||
| Assess | ||||||
| MHC I A02 Allele presenting YLQPRTFLL |
Heteromer P0DTC2; P61769; | 6×EDO; 1×ACT; 1×CA; | ||||
| Assess | ||||||
| HLA-A*02:01 bound to Neuroblastoma Derived IGFBPL1 peptide |
Heteromer P61769; Q8WX77; | 1×GOL; | ||||
| Assess | ||||||
| MHC I A02 Allele presenting YLQLRTFLL |
Heteromer P0DTC2; P61769; | 12×IOD; 1×PEG; | ||||
| Assess | ||||||
| Human Class I Major Histocompatibility Complex, A02 allele, presenting IIGWMWIPV |
Heteromer P61769; | 5×EDO; 1×GOL; 3×SO4; 1×NA; 1×P4G; | ||||
| Assess | ||||||
| MHC Class I A02 Allele presenting LLLGIGILVL, in complex with Mel5 TCR |
Heteromer P61769; Q10589; | 4×GOL; | ||||
| Assess | ||||||
| Crystal Structure of HLA-A*02:01 in complex with KLNDLCFTNV, an 10-mer epitope from SARS-CoV-2 Spik… |
Heteromer P0DTC2; P61769; | 1×GOL; | ||||
| Assess | ||||||
| MHC Class I A02 Allele presenting NLSALGIFST |
Heteromer P61769; Q9Y6M1; | 3×PEG; 2×SO4; 1×EDO; | ||||
| Assess | ||||||
| MHC Class I A02 Allele presenting NLSALGIFST, in complex with Mel5 TCR |
Heteromer P61769; Q9Y6M1; | 2×EDO; | ||||
| Assess | ||||||
| Human Class I Major Histocompatibility Complex, A02 allele, presenting LLS (t-butyl)Y FGTPT |
Heteromer P61769; | 2×SO4; | ||||
| Assess | ||||||
| Emergence of immune escape at dominant SARS-CoV-2 killer T-cell epitope |
Heteromer P0DTC2; P61769; | 1×PEG; 3×SO4; | ||||
| Assess | ||||||
| HLA-A*02:01 bound to Neuroblastoma Derived IGFBPL1 peptide |
Heteromer P61769; Q8WX77; | 1×GOL; | ||||
| Assess | ||||||
| HLA-A*02:01 bound to Neuroblastoma Derived mutant IGFBPL1 peptide |
Heteromer P61769; Q8WX77; | |||||
| Assess | ||||||
| Human Class I MHC HLA-A2 in complex with AVGSYVYSV peptide |
Heteromer P61769; Q15124; | |||||
| Assess | ||||||
| HLA-A*02:01 bound to Neuroblastoma Derived IGFBPL1 peptide |
Heteromer P61769; Q8WX77; | 3×GOL; | ||||
| Assess | ||||||
| SARS-CoV-2 YLQ peptide binds to HLA-A2 |
Heteromer P0DTC2; P61769; | 1×PG4; | ||||
| Assess | ||||||
| Human Class I MHC HLA-A2 in complex with sorting nexin 24 (127-135) peptide KLSHQPVLL |
Heteromer P61769; Q9Y343; | 1×NO3; | ||||
| Assess | ||||||
| HLA peptide complex |
Heteromer P0DTC2; P61769; | 4×EDO; | ||||
| Assess | ||||||
| Complex of HLA-A2, a class I MHC, with a p53 peptide |
Heteromer P04637; P61769; | |||||
| Assess | ||||||
| SILv44 T cell receptor bound to HLA-A2 presenting gp100 peptide (ITDQVPFSV) |
Heteromer P40967; P61769; | 3×GOL; | ||||
| Assess | ||||||
| SILv44 T cell receptor bound to HLA-A2 presenting gp100T2M peptide (IMDQVPFSV) |
Heteromer P40967; P61769; | 1×FLC; | ||||
| Assess | ||||||
| SARS-CoV-2 specific private TCR RLQ7 in complex with RLQ-T1006I-HLA-A2 |
Heteromer P0DTC2; P61769; | 1×PG4; | ||||
| Assess | ||||||
| Human Class I Major Histocompatibility Complex, A02 allele, presenting LLGWVFAQV |
Heteromer P13726; P61769; | |||||
| Assess | ||||||
| T4H2 T cell receptor bound to HLA-A2 presenting gp100 peptide (ITDQVPFSV) |
Heteromer P40967; P61769; | |||||
| Assess | ||||||
| SARS-CoV-2 specific private TCR RLQ7 in complex with RLQ-HLA-A2 |
Heteromer P0DTC2; P61769; | 1×PG4; | ||||
| Assess | ||||||
| Class I MHC (HLA-A*02) presenting alpha fetoprotein peptide (AFP) |
Heteromer P02771; P61769; | 3×PGE; 5×PEG; 1×1PE; | ||||
| Assess | ||||||
| T4H2 T cell receptor bound to HLA-A2 presenting gp100T2L peptide (ILDQVPFSV) |
Heteromer P40967; P61769; | 1×GOL; | ||||
| Assess | ||||||
| Human Class I MHC HLA-A2 bound to sorting nexin 24 (127-135) neoantigen KLSHQLVLL |
Heteromer P61769; Q9Y343; | 1×PEG; | ||||
| Assess | ||||||
| T4H2 T cell receptor bound to HLA-A2 presenting gp100T2M peptide (IMDQVPFSV) |
Heteromer P40967; P61769; | |||||
| Assess | ||||||
| Noncanonical binding of single-chain A6 TCR variant S3-4 in complex with Tax/HLA-A2 |
Heteromer P14079; P61769; | 1×MES; | ||||
| Assess | ||||||
| Structure of HLA-A2:01 with peptide MM92 |
Heteromer P01116; P61769; | 3×GOL; 6×NA; 1×SO4; | ||||
| Assess | ||||||
| Structure of HLA-A2:01 with peptide MM90 |
Heteromer P01116; P61769; | 6×GOL; 5×NA; | ||||
| Assess | ||||||
| Structure of HLA-A2:01 with peptide MM91 |
Heteromer P01116; P61769; | 3×GOL; 4×NA; | ||||
| Assess | ||||||
| Human leukocyte antigen A*0201 in complex with SARS-CoV-2 epitope YLQPRTFLL |
Heteromer P0DTC2; P61769; | 4×GOL; | ||||
| Assess | ||||||
| Human leukocyte antigen A*0201 in complex with SARS-CoV2 epitope KLWAQCVQL |
Heteromer P0DTD1; P61769; | 2×GOL; | ||||
| Assess | ||||||
| SARS-CoV-2 RLQ peptide-specific TCR pRLQ3 binds to RLQ-HLA-A2 |
Heteromer P0DTC2; P61769; | |||||
| Assess | ||||||
| Complex of HLA-A2, a class I MHC, with a p53 peptide |
Heteromer P04637; P61769; | |||||
| Assess | ||||||
| Human leukocyte antigen A*0201 in complex with SARS-CoV2 epitope ALWEIQQVV |
Heteromer P0DTD1; P61769; | 3×GOL; 2×PGE; | ||||
| Assess | ||||||
| T cell receptor-p53-HLA-A2 complex |
Heteromer P04637; P61769; | |||||
| Assess | ||||||
| CRYSTAL STRUCTURE OF HLA-A2-WT1-RMF AND FAB 11D06 |
Heteromer P19544; P61769; | 5×NA; | ||||
| Assess | ||||||
| SARS-CoV-2 RLQ peptide binds to HLA-A2 |
Heteromer P0DTC2; P61769; | |||||
| Assess | ||||||
| TCR peptide HLA-A2 complex |
Heteromer P0DTC2; P61769; | |||||
| Assess | ||||||
| Structure of HLA-A2:01 with peptide MM96 |
Heteromer P01116; P61769; | 4×GOL; 1×SO4; 2×NA; | ||||
| Assess | ||||||
| T cell receptor-p53-HLA-A2 complex |
Heteromer P04637; P61769; | |||||
| Assess | ||||||
| T cell receptor-p53-HLA-A2 complex |
Heteromer P04637; P61769; | |||||
| Assess | ||||||
| SARS-CoV-2 YLQ peptide-specific TCR pYLQ7 binds to YLQ-HLA-A2 |
Heteromer P0DTC2; P61769; | |||||
| Assess | ||||||
| Structure of the antibody fragment H2 in complex with HLA-A*02:01/p53R175H |
Heteromer P04637; P61769; | |||||
| Assess | ||||||
1 SWISS-MODEL model
| Template | Oligo-state | QMEANDisCo | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 7u1r.1.A | monomer | 0.84 | 1×ARG; | 99.45 | ||
| Assess | ||||||